钦伦秀

教授,博士生导师,复旦大学附属华山医院外科主任

复旦大学附属华山医院 外科主任/华山北院常务副院长

复旦大学肿瘤转移研究所所长

联系方式:电话:021-52887172 传真:021-52887172

邮箱:qinlx@fudan.edu.cn

研究方向:提高消化系统肿瘤外科疗效的关键措施

教育背景

1987年毕业于原徐州医学院临床医学专业,获学士学位

1990年获原徐州医学院外科学硕士学位

1996年获原上海医科大学外科学博士学位

教学及科研情况

主要从事肝胆外科临床工作30年,每年手术治疗肝胆肿瘤病人400余例。同时从事肿瘤转移复发研究,先后承担国家科技重大专项、973、国家自然基金重点、重大研究计划以及国际合作重大项目等多项课题。发表SCI论文180余篇,通讯/第一作者90篇(14篇IF>10),包括Cancer Cell, Cell Metabolism, Gut, Hepatology等,连续三年入选中国高被引学者榜单(hi-index 54)。主编专著3本,副主编3本,主译专著1本。获专利12项。第一完成人获国家自然科学二等奖1项、省部级一等奖2项;第五完成人获国家科技进步一等奖1项。

获上海市自然科学牡丹奖、谈家桢生命科学奖创新奖、上海市五一劳动奖章、上海工匠等奖励和荣誉,曾获国家杰出青年基金、教育部长江特聘教授。

学术任职

现任复旦大学附属华山医院外科主任/华山医院北院常务副院长,复旦大学肿瘤转移研究所所长。国家杰出青年基金获得者、长江学者特聘教授、教育部创新团队带头人、973首席科学家,享受国务院特殊津贴。

兼任中国临床肿瘤学会(CSCO)理事/胆道肿瘤专委会副主委,中国抗癌协会肿瘤精准治疗专委会主委/肿瘤转移专委会名誉主委,中华医学会外科分会委员/肝脏外科学组委员,中国研究型医院协会消化外科分会副会长,中国老年医学会肿瘤分会副会长,上海医师协会外科分会副会长。

担任Clin Exp Metastasis,Neoplasia等杂志编委。

近五年主要论文

1. Zhang Z, Li TE, Chen M, Xu D, Zhu Y, Hu BY, Lin ZF, Pan JJ, Wang X, Wu C, Zheng Y, Lu L, Jia HL, Gao S, Dong QZ, Qin LX. MFN1-dependent alteration of mitochondrial dynamics drives hepatocellular carcinoma metastasis by glucose metabolic reprogramming. Br J Cancer. 2020 Jan;122(2):209-220.

2. Yang LY, Luo Q, Lu L, Zhu WW, Sun HT, Wei R, Lin ZF, Wang XY, Wang CQ, Lu M, Jia HL, Chen JH, Zhang JB, Qin LX. Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma via provoking tumorous inflammatory response. J Hematol Oncol. 2020 Jan 6;13(1):3.

3. Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, Li CW, Lim SO, Sheng YY, Zhang Y, Li JH, Luo Q, Zheng Y, Zhao Y, Lu L, Jia HL, Hung MC, Dong QZ, Qin LX. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut. 2019 Sep;68(9):1653-1666.

4. Lu M, Zhu WW, Wang X, Tang JJ, Zhang KL, Yu GY, Shao WQ, Lin ZF, Wang SH, Lu L, Zhou J, Wang LX, Jia HL, Dong QZ, Chen JH, Lu JQ, Qin LX. ACOT12-Dependent Alteration of Acetyl-CoA drives hepatocellular carcinoma metastasis by epigenetic induction of epithelial-mesenchymal transition. Cell Metabolism. 2019 Apr 2;29(4):886-900.

5. Kadel D, Zhang Y, Sun HR, Zhao Y, Dong QZ, Qin LX. Current perspectives of cancer-associated fibroblast in therapeutic resistance: potential mechanism and future strategy. Cell Biol Toxicol. 2019 Oct;35(5):407-421.

6. Sheng Y, Wei J, Zhang Y, Gao X, Wang Z, Yang J, Yan S, Zhu Y, Zhang Z, Xu D, Wang C, Zheng Y, Dong Q, Qin L. Mutated EPHA2 is a target for combating lymphaticmetastasis in intrahepatic cholangiocarcinoma. Int J Cancer. 2019 May 15;144(10):2440-2452.

7. Zhao J, Du P, Cui P, Qin Y, Hu C, Wu J, Zhou Z, Zhang W, Qin L, Huang G. LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer. Oncogene. 2018 Jul;37(30):4094-4109.

8. Zhu Y, Gao XM, Yang J, Xu D, Zhang Y, Lu M, Zhang Z, Sheng YY, Li JH, Yu XX, Zheng Y, Dong QZ, Qin LX. C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma. Cancer Sci. 2018 Mar;109(3):710-723.

9. Luo Q, Wang CQ, Yang LY, Gao XM, Sun HT, Zhang Y, Zhang KL, Zhu Y, Zheng Y,Sheng YY, Lu L, Jia HL, Yu WQ, Liu J, Dong QZ, Qin LX. FOXQ1/NDRG1 axis exacerbates hepatocellular carcinoma initiation via enhancing crosstalk between fibroblasts and tumor cells. Cancer Lett. 2018 Mar 28;417:21-34.

10. Gao X, Sheng Y, Yang J, Wang C, Zhang R, Zhu Y, Zhang Z, Zhang K, Yan S, Sun H, Wei J, Wang X, Yu X, Zhang Y, Luo Q, Zheng Y, Qiao P, Zhao Y, Dong Q, Qin L. Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma. J Exp Clin Cancer Res. 2018 Jul 31;37(1):179.

11. Zhang Y, Gao X, Zhu Y, Kadel D, Sun H, Chen J, Luo Q, Sun H, Yang L, Yang J, Sheng Y, Zheng Y, Zhu K, Dong Q, Qin L. The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res. 2018 Apr 30;37(1):93. doi: 10.1186/s13046-018-0750-2.

12. Liu Y, Zhang Y, Wang S, Dong QZ, Shen Z, Wang W, Tao S, Gu C, Liu J, Xie Y, Qin LX. Prospero-related homeobox 1 drives angiogenesis of hepatocellular carcinoma through selectively activating interleukin-8 expression. Hepatology. 2017 Dec;66(6):1894-1909.

13. Wang XY, Wang Z, Huang JB, Ren XD, Ye D, Zhu WW, Qin LX. Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer. Tumour Biol. 2017 Jun;39(6):1010428317699111.

14. Kong Y, Sun L, Hou Z, Zhang Y, Chen P, Cui Y, Zhu X, Song T, Li Q, Li H, Zhang T, Qin L. Apatinib is effective for treatment of advanced hepatocellular carcinoma. Oncotarget. 2017 Nov 6;8(62):105596-105605.

15. Gao XM, Zhang R, Dong QZ, Qin LX. Properties and feasibility of using cancer stem cells in clinical cancer treatment. Cancer Biol Med. 2016 Dec;13(4):489-495.

16. Zhang XF, Yang X, Jia HL, Zhu WW, Lu L, Shi W, Zhang H, Chen JH, Tao YF, Wang ZX, Yang J, Wang LX, Lu M, Zheng Y, Zhao J, Dong QZ, Qin LX. Bcl-2 expression is a poor predictor for hepatocellular carcinoma prognosis of andropause-age patients. Cancer Biol Med. 2016 Dec;13(4):459-468.

17. Wang CQ, Sun HT, Gao XM, Ren N, Sheng YY, Wang Z, Zheng Y, Wei JW, Zhang KL, Yu XX, Zhu Y, Luo Q, Yang LY, Dong QZ, Qin LX. Interleukin-6 enhances cancer stemness and promotes metastasis of hepatocellular carcinoma via up-regulating osteopontin expression. Am J Cancer Res. 2016 Sep 1;6(9):1873-1889.

18. Ye QH, Zhu WW, Zhang JB, Qin Y, Lu M, Lin GL, Guo L, Zhang B, Lin ZH, Roessler S, Forgues M, Jia HL, Lu L, Zhang XF, Lian BF, Xie L, Dong QZ, Tang ZY, Wang XW, Qin LX. GOLM1 modulates EGFR/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis. Cancer Cell. 2016 Sep 12;30(3):444-58.